Item Type | Name |
Concept
|
Head and Neck Neoplasms
|
Academic Article
|
A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303).
|
Academic Article
|
Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer.
|
Academic Article
|
Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group.
|
Academic Article
|
Planned post-chemoradiation neck dissection: significance of radiation dose.
|
Academic Article
|
Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients.
|
Academic Article
|
A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer.
|
Academic Article
|
Emerging molecular targeted therapies in squamous cell carcinoma of the head and neck.
|
Academic Article
|
The impact of tumor volume and radiotherapy dose on outcome in previously irradiated recurrent squamous cell carcinoma of the head and neck treated with stereotactic body radiation therapy.
|
Academic Article
|
Update on chemoradiotherapy for head and neck cancer.
|
Academic Article
|
Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer.
|
Academic Article
|
Phase I dendritic cell p53 peptide vaccine for head and neck cancer.
|
Academic Article
|
Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer.
|
Academic Article
|
Posttraumatic stress disorder symptoms in newly diagnosed patients with head and neck cancer and their partners.
|
Academic Article
|
Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer.
|
Academic Article
|
Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas.
|
Academic Article
|
Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell carcinoma of the head and neck.
|
Academic Article
|
Phase II study of cetuximab in combination with cisplatin and radiation in unresectable, locally advanced head and neck squamous cell carcinoma: Eastern cooperative oncology group trial E3303.
|
Academic Article
|
Epidemiology, staging, and screening of head and neck cancer.
|
Academic Article
|
Deferring planned neck dissection following chemoradiation for stage IV head and neck cancer: the utility of PET-CT.
|
Academic Article
|
A randomized validation study comparing embedded versus extracted FACT Head and Neck Symptom Index scores.
|
Academic Article
|
Targeting GPCR-mediated p70S6K activity may improve head and neck cancer response to cetuximab.
|
Academic Article
|
Clinical applications of gene therapy in head and neck cancer.
|
Academic Article
|
XPF expression correlates with clinical outcome in squamous cell carcinoma of the head and neck.
|
Academic Article
|
Long-term results of a phase III randomized trial of postoperative radiotherapy with or without carboplatin in patients with high-risk head and neck cancer.
|
Academic Article
|
Intensive concurrent chemoradiotherapy for head and neck cancer with 5-Fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure.
|
Academic Article
|
Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer.
|
Academic Article
|
Swallowing dysfunction--preventative and rehabilitation strategies in patients with head-and-neck cancers treated with surgery, radiotherapy, and chemotherapy: a critical review.
|
Academic Article
|
Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer.
|
Academic Article
|
Targeting angiogenesis in head and neck cancer.
|
Academic Article
|
Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy.
|
Academic Article
|
Head and neck cancer.
|
Academic Article
|
CTLA-4? Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis.
|
Academic Article
|
Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy.
|
Academic Article
|
EGFR inhibition for recurrent or metastatic HNSCC.
|
Academic Article
|
Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer.
|
Academic Article
|
Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis : results from a Northwestern University Costs of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received care at a county hospital, a Veterans Administration hospital, or a comprehensive cancer care center.
|
Academic Article
|
Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma.
|
Academic Article
|
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck.
|
Academic Article
|
Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck.
|
Academic Article
|
Serum biomarker modulation following molecular targeting of epidermal growth factor and cyclooxygenase pathways: a pilot randomized trial in head and neck cancer.
|
Academic Article
|
Intratumoral epidermal growth factor receptor antisense DNA therapy in head and neck cancer: first human application and potential antitumor mechanisms.
|
Academic Article
|
Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (E1304): a trial of the Eastern Cooperative Oncology Group.
|
Academic Article
|
Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy.
|
Academic Article
|
Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: results of a phase I dose-escalation trial.
|
Academic Article
|
Characterization of human papillomavirus antibodies in individuals with head and neck cancer.
|
Academic Article
|
Revisiting induction chemotherapy for head and neck cancer.
|
Academic Article
|
Induction chemotherapy for head and neck cancer: will history repeat itself?
|
Academic Article
|
Revisiting induction chemotherapy for head and neck cancer. References and reviews.
|
Academic Article
|
Management of patients treated with chemoradiotherapy for head and neck cancer without prophylactic feeding tubes: the University of Pittsburgh experience.
|
Academic Article
|
Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial.
|
Academic Article
|
Pemetrexed in head and neck cancer: a systematic review.
|
Academic Article
|
The impact of health insurance status on the survival of patients with head and neck cancer.
|
Academic Article
|
Current status and future directions in induction chemotherapy for head and neck cancer.
|
Academic Article
|
Increased PD-1+ and TIM-3+ TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients.
|
Academic Article
|
Phase 1 study of EGFR-antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives.
|
Academic Article
|
Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer.
|
Academic Article
|
Editorial: Advances in the Systemic Therapy and Combined Modality Approaches for Head and Neck Cancer.
|
Academic Article
|
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group.
|
Academic Article
|
Nivolumab and ipilimumab in combination with radiotherapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck.
|
Academic Article
|
Effect of preoperative programmed death-1 or programmed death ligand-1 immune check point inhibition on complications after surgery for primary head and neck cancer.
|
Academic Article
|
A new prognostic model in chemotherapy-treated patients with recurrent or metastatic head and neck cancer: An analysis of ECOG-ACRIN E1305.
|
Academic Article
|
Association of a gene-expression subtype to outcome and treatment response in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab.
|
Academic Article
|
Predictive capacity of immune-related adverse events and cytokine profiling in neoadjuvant immune checkpoint inhibitor trials for head and neck squamous cell carcinoma.
|